ATE330620T1 - Verwendung von midkin oder von anti-midkin antikörper - Google Patents

Verwendung von midkin oder von anti-midkin antikörper

Info

Publication number
ATE330620T1
ATE330620T1 AT98931102T AT98931102T ATE330620T1 AT E330620 T1 ATE330620 T1 AT E330620T1 AT 98931102 T AT98931102 T AT 98931102T AT 98931102 T AT98931102 T AT 98931102T AT E330620 T1 ATE330620 T1 AT E330620T1
Authority
AT
Austria
Prior art keywords
midkin
antibodies
midkine
inducible
heparin
Prior art date
Application number
AT98931102T
Other languages
English (en)
Inventor
Takashi Muramatsu
Tohru Takada
Kazuhiro Toriyama
Hisako Muramatsu
Original Assignee
Takashi Muramatsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takashi Muramatsu filed Critical Takashi Muramatsu
Application granted granted Critical
Publication of ATE330620T1 publication Critical patent/ATE330620T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT98931102T 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper ATE330620T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20533297 1997-07-14
JP20532097 1997-07-14

Publications (1)

Publication Number Publication Date
ATE330620T1 true ATE330620T1 (de) 2006-07-15

Family

ID=26515003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931102T ATE330620T1 (de) 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper

Country Status (10)

Country Link
US (1) US7390491B2 (de)
EP (1) EP0998941B9 (de)
JP (1) JP2010215673A (de)
KR (1) KR100571010B1 (de)
CN (1) CN1287852C (de)
AT (1) ATE330620T1 (de)
AU (1) AU756279B2 (de)
CA (1) CA2296409C (de)
DE (1) DE69835016T2 (de)
WO (1) WO1999003493A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00010110A (es) * 1998-04-17 2002-08-06 Angiogenix Inc Factores angiogenicos terapeuticos y metodos para su uso.
JP4228111B2 (ja) * 1998-08-24 2009-02-25 メディカル セラピーズ リミテッド 動脈硬化およびｐｔｃａ術後の血管再狭窄に対する予防・治療剤
US20060259026A1 (en) * 2005-05-05 2006-11-16 Baylis Medical Company Inc. Electrosurgical treatment method and device
WO2004078210A1 (ja) * 2003-03-06 2004-09-16 Takashi Muramatsu 開腹手術後の癒着の予防剤
JP4646070B2 (ja) * 2003-03-27 2011-03-09 メディカル セラピーズ リミテッド 関節炎関連遺伝子及びこれの関節炎検査等への利用
EP1964574B1 (de) 2005-11-14 2016-09-07 Cellmid Limited Verfahren zur behandlung oder prävention von krankheiten im zusammenhang mit funktionalen störungen der regulatorischen t-zelle
US9163081B2 (en) 2006-11-14 2015-10-20 Medical Therapies Limited Antibody recognizing C-domain of midkine
ZA200903562B (en) * 2006-11-14 2010-07-28 Ribomic Inc Aptamer against midkine and use thereof
WO2010074218A1 (ja) * 2008-12-25 2010-07-01 株式会社イーベック 抗ヒトミッドカイン抗体
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
WO2012122590A1 (en) 2011-03-14 2012-09-20 Cellmid Limited Antibody recognizing n-domain of midkine
EP2881467B1 (de) 2012-07-30 2018-10-31 National University Corporation Nagoya University Monoklonaler antikörper gegen menschlichen midkine
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206223A (en) * 1986-06-26 1993-04-27 Yeda Research And Development Co. Ltd. Method for inhibiting heparanase activity
IL79254A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
WO1992019249A1 (en) 1991-05-02 1992-11-12 Yeda Research And Development Co. Ltd. Compositions for the prevention and/or treatment of pathological processes
EP0535336A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Mk protein as cell growth inhibitor
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
WO1994028889A1 (en) * 1993-06-08 1994-12-22 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
JPH08277224A (ja) * 1995-02-07 1996-10-22 Shiseido Co Ltd 抗炎症剤
EP0754460B1 (de) 1995-02-07 2002-06-05 Shiseido Company Limited Anti-inflamatorische agenzien
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
JPH0995454A (ja) * 1995-10-02 1997-04-08 Meiji Milk Prod Co Ltd 抗潰瘍組成物
EP0937461B1 (de) * 1996-07-10 2005-07-06 Meiji Dairies Corporation Verwendung von proteinen aus der mk familie als hämatopoietischer faktor

Also Published As

Publication number Publication date
AU8131098A (en) 1999-02-10
CN1287852C (zh) 2006-12-06
CA2296409A1 (en) 1999-01-28
EP0998941B9 (de) 2007-03-14
EP0998941A1 (de) 2000-05-10
US7390491B2 (en) 2008-06-24
KR100571010B1 (ko) 2006-04-13
EP0998941A4 (de) 2004-05-12
EP0998941B1 (de) 2006-06-21
CN1306435A (zh) 2001-08-01
WO1999003493A1 (en) 1999-01-28
KR20010021814A (ko) 2001-03-15
CA2296409C (en) 2010-05-18
DE69835016T2 (de) 2007-06-28
DE69835016D1 (de) 2006-08-03
JP2010215673A (ja) 2010-09-30
US20030072739A1 (en) 2003-04-17
AU756279B2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
DE69835016D1 (de) Verwendung von midkin oder von anti-midkin antikörper
DE3667378D1 (de) Verwendung von n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthioharnstoff zur bekaempfung von weissen fliegen.
ATE454141T1 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
DE69008423D1 (de) Dynamische Fixierung von Schweinsaortaklappen.
ATE286510T1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69001839D1 (de) 1-hydroxyvitamin d2-epimer und dessen derivate.
EA199900279A1 (ru) Производные бензамида и их применение в качестве лекарственных средств с лтв4-антагонистической активностью
ES2058599T3 (es) Procedimiento para mejorar la eficacia de las toxinas de insectos.
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
DE3680000D1 (de) Stabilisierte aktive formen von vitamin-d3.
ATE208042T1 (de) Hapten-analoge zur verwendung in immunoassays
DE69319576D1 (de) Verwendung von Furanonen wie Duftstoffe
ATE172721T1 (de) Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ATE222896T1 (de) Substituierte thiazoline und ihre verwendung zur bekämpfung von tierischen schädlingen
DE69227805D1 (de) Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
DE3871712D1 (de) Suspensionen und verwendung dieser suspensionen.
DE69017825D1 (de) Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester.
FI883723A7 (fi) Ihmisen monoklonaaliset vasta-aineet ja niitä vaikuttavana aineosana s isältävät terapeuttiset aineet infektiotauteja vastaan

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties